Leerink Partnrs Brokers Lift Earnings Estimates for NBIX

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Research analysts at Leerink Partnrs raised their Q4 2024 earnings per share (EPS) estimates for Neurocrine Biosciences in a report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of $1.97 per share for the quarter, up from their prior estimate of $1.84. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.19 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences’ FY2025 earnings at $7.65 EPS, FY2026 earnings at $9.80 EPS, FY2027 earnings at $12.00 EPS and FY2028 earnings at $13.95 EPS.

NBIX has been the subject of a number of other reports. Oppenheimer boosted their price objective on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Guggenheim boosted their price target on Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 4th. Jefferies Financial Group boosted their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research report on Monday, August 19th. Finally, BMO Capital Markets dropped their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Trading Down 0.4 %

Shares of NASDAQ:NBIX opened at $118.01 on Thursday. The company has a market capitalization of $11.88 billion, a PE ratio of 32.51 and a beta of 0.36. Neurocrine Biosciences has a 12-month low of $103.63 and a 12-month high of $157.98. The business has a 50 day moving average of $126.01 and a two-hundred day moving average of $134.82.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The company had revenue of $590.20 million during the quarter, compared to analyst estimates of $545.98 million. During the same period in the previous year, the firm posted $0.95 earnings per share. The company’s revenue was up 30.4% compared to the same quarter last year.

Institutional Investors Weigh In On Neurocrine Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. RFP Financial Group LLC lifted its stake in Neurocrine Biosciences by 346.5% in the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after buying an additional 149 shares during the last quarter. Mather Group LLC. purchased a new stake in Neurocrine Biosciences in the 1st quarter valued at $26,000. Ashton Thomas Private Wealth LLC purchased a new stake in Neurocrine Biosciences in the 2nd quarter valued at $28,000. Innealta Capital LLC purchased a new stake in Neurocrine Biosciences in the 2nd quarter valued at $30,000. Finally, New Covenant Trust Company N.A. purchased a new stake in Neurocrine Biosciences in the 1st quarter valued at $32,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director Gary A. Lyons sold 11,570 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.43, for a total transaction of $1,740,475.10. Following the sale, the director now owns 119,047 shares in the company, valued at $17,908,240.21. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Gary A. Lyons sold 11,570 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.43, for a total value of $1,740,475.10. Following the transaction, the director now owns 119,047 shares in the company, valued at approximately $17,908,240.21. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Matt Abernethy sold 14,100 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.38, for a total value of $2,120,358.00. Following the sale, the chief financial officer now directly owns 31,528 shares in the company, valued at $4,741,180.64. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,968 shares of company stock worth $8,999,632 in the last quarter. 4.30% of the stock is owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.